Switch theme
Sign up to access all valuation multiples
Beijing Wantai Biological Pharmacy Enterprise Co Ltd is engaged in Research, development, production and sales of in vitro diagnostic reagents, instruments and vaccines.
1991
n/a
Last FY Revenue $312M
Last FY EBITDA $52.3M
$11.7B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Wantai BioPharm achieved revenue of $312M and an EBITDA of $52.3M.
Wantai BioPharm expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Wantai BioPharm valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | n/a | XXX | $312M | XXX | XXX | XXX |
| Gross Profit | n/a | XXX | $206M | XXX | XXX | XXX |
| Gross Margin | n/a | XXX | 66% | XXX | XXX | XXX |
| EBITDA | n/a | XXX | $52.3M | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBIT | n/a | XXX | $0.3M | XXX | XXX | XXX |
| EBIT Margin | n/a | XXX | 0% | XXX | XXX | XXX |
| Net Profit | $15.7M | XXX | $14.7M | XXX | XXX | XXX |
| Net Margin | n/a | XXX | 5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Wantai BioPharm's stock price is CNY 69 (or $10).
Wantai BioPharm has current market cap of CNY 87.7B (or $12.2B), and EV of CNY 84.1B (or $11.7B).
See Wantai BioPharm trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $11.7B | $12.2B | XXX | XXX | XXX | XXX | $0.01 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Wantai BioPharm has market cap of $12.2B and EV of $11.7B.
Wantai BioPharm's trades at 37.5x EV/Revenue multiple, and 223.5x EV/EBITDA.
Equity research analysts estimate Wantai BioPharm's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Wantai BioPharm has a P/E ratio of 776.0x.
See valuation multiples for Wantai BioPharm and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $12.2B | XXX | $12.2B | XXX | XXX | XXX |
| EV (current) | $11.7B | XXX | $11.7B | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 37.5x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 223.5x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | 36573.4x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | 776.0x | XXX | 825.3x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -158.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialWantai BioPharm's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Wantai BioPharm's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Wantai BioPharm's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Wantai BioPharm and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | 13% | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 17% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | -43% | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 17% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 39% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 66% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| CSL | XXX | XXX | XXX | XXX | XXX | XXX |
| Imugene | XXX | XXX | XXX | XXX | XXX | XXX |
| Prescient Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| GSK India | XXX | XXX | XXX | XXX | XXX | XXX |
| AstraZeneca India | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Wantai BioPharm acquired XXX companies to date.
Last acquisition by Wantai BioPharm was XXXXXXXX, XXXXX XXXXX XXXXXX . Wantai BioPharm acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Wantai BioPharm founded? | Wantai BioPharm was founded in 1991. |
| Where is Wantai BioPharm headquartered? | Wantai BioPharm is headquartered in China. |
| Is Wantai BioPharm publicy listed? | Yes, Wantai BioPharm is a public company listed on SHG. |
| What is the stock symbol of Wantai BioPharm? | Wantai BioPharm trades under 603392 ticker. |
| When did Wantai BioPharm go public? | Wantai BioPharm went public in 2020. |
| Who are competitors of Wantai BioPharm? | Similar companies to Wantai BioPharm include e.g. CSL, Imugene, Prescient Therapeutics, GSK India. |
| What is the current market cap of Wantai BioPharm? | Wantai BioPharm's current market cap is $12.2B |
| Is Wantai BioPharm profitable? | Yes, Wantai BioPharm is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
